An end-of-year sequencing survey of GenomeWeb readers reveals that Illumina has solidified its dominant market position in next-gen sequencing over the last year.

The overall picture holds true for the clinical sequencing market as well, assessed for the first time this year, where Illumina's leadership is even more pronounced.

When it comes to purchasing plans, Illumina is rivaled by Oxford Nanopore Technologies, which recently started an early access program for its first commercial platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.